Aarkstore - Obsessive-Compulsive Disorder-Api Insights, 2014

Aarkstore Enterprise

7th January 2015

Aarkstore - Obsessive-Compulsive Disorder-API Insights, 2014

Browse Full Report @ http://www.aarkstore.com/pharmaceuticals-healthcare/87933/obsessivecompulsive-disorder-api-insights-2014 Published: Nov 2014 | No. Of Pages: 60 Pages PDF: $ 1250 | Multi User Licence: $ 2500

The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.

India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.

Aarkstore Enterprise

DelveInsights, Obsessive-Compulsive Disorder -API Insights, 2014 Report describes the current therapeutics that are propelling the pharmaceutical markets worldwide. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the Obsessive-Compulsive Disorder. It also provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent and patent exclusivity information. The research analysis also presents the global sales forecasts data till 2015.

DATA SOURCES

The report is built using data and information sourced from proprietary...